N

Intellia Therapeutics
D

NTLA

14.080
USD
0.29
(2.10%)
Market Open
Volume
8,660
EPS
-5
Div Yield
-
P/E
-3
Market Cap
1,436,064,865
Related Instruments
    A
    ABUS
    0.01000
    (0.28%)
    3.64000 USD
    B
    BEAM
    -2.275
    (-8.65%)
    24.035 USD
    B
    BNTX
    -3.740
    (-3.61%)
    99.740 USD
    C
    CRSP
    0.360
    (0.77%)
    47.280 USD
    E
    EDIT
    -0.11500
    (-4.14%)
    2.66500 USD
    More
News

Title: Intellia Therapeutics

Sector: Healthcare
Industry: Biotechnology
Intellia Therapeutics is a gene editing company focused on the development of Crispr/Cas9-based therapeutics. Crispr/Cas9 stands for Clustered Regularly Interspaced Short Palindromic Repeats (Crispr)/Crispr-associated protein 9 (Cas9), which is a revolutionary technology for precisely altering specific sequences of genomic DNA. Intellia is focused on using this technology to treat genetically defined diseases. It's evaluating multiple gene editing approaches using in vivo and ex vivo therapies to address diseases with high unmet medical needs, including ATTR amyloidosis, hereditary angioedema, sickle cell disease, and immuno-oncology. Intellia has formed collaborations with several companies to advance its pipeline, including narrow-moat Regeneron and wide-moat Novartis.